Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Deferred Taxes (2020 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed Deferred Taxes for 6 consecutive years, with $4.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Deferred Taxes rose 276.56% year-over-year to $4.5 million, compared with a TTM value of $6.8 million through Dec 2025, down 27.05%, and an annual FY2025 reading of $6.8 million, down 27.05% over the prior year.
  • Deferred Taxes was $4.5 million for Q4 2025 at Catalyst Pharmaceuticals, up from -$2.4 million in the prior quarter.
  • Across five years, Deferred Taxes topped out at $13.9 million in Q3 2023 and bottomed at -$2.7 million in Q4 2021.
  • Average Deferred Taxes over 5 years is $990100.0, with a median of -$850000.0 recorded in 2022.
  • The sharpest move saw Deferred Taxes crashed 269.03% in 2021, then skyrocketed 1592.83% in 2023.
  • Year by year, Deferred Taxes stood at -$2.7 million in 2021, then skyrocketed by 53.19% to -$1.3 million in 2022, then skyrocketed by 31.28% to -$883000.0 in 2023, then plummeted by 189.35% to -$2.6 million in 2024, then soared by 276.56% to $4.5 million in 2025.
  • Business Quant data shows Deferred Taxes for CPRX at $4.5 million in Q4 2025, -$2.4 million in Q3 2025, and $2.4 million in Q2 2025.